Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer Alaa T. AlshareedaOla H. NegmEmad A. Rakha Preclinical study 28 April 2013 Pages: 301 - 310
Micro-computed tomography (Micro-CT): a novel approach for intraoperative breast cancer specimen imaging Rong TangJulliette M. BuckleyBarbara L. Smith Preclinical study 14 May 2013 Pages: 311 - 316
Platform comparisons for identification of breast cancers with a BRCA-like copy number profile Philip C. SchoutenEwald van DykPetra M. Nederlof Preclinical study 14 May 2013 Pages: 317 - 327
The impact of cyclin D1 overexpression on the prognosis of ER-positive breast cancers: a meta-analysis Xiao-Ling XuShu-Zheng ChenWei-Min Mao Preclinical study 14 May 2013 Pages: 329 - 339
DNA promoter hypermethylation profiles in breast duct fluid Dominique TwelvesAshutosh NerurkarClare M. Isacke Preclinical study 15 May 2013 Pages: 341 - 350
Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells Xihong ZhangMichael R. DiazDouglas Yee Preclinical study 18 May 2013 Pages: 351 - 360
Rank-based predictors for response and prognosis of neoadjuvant taxane-anthracycline-based chemotherapy in breast cancer Lin ZhangChunxiang HaoZheng Guo Preclinical study 22 May 2013 Pages: 361 - 369
Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854) T. J. A. DekkerC. J. H. van de VeldeW. E. Mesker Preclinical study 25 May 2013 Pages: 371 - 379
FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast Aseem LalLoretta ChanE. Shelley Hwang Preclinical study 28 May 2013 Pages: 381 - 390
Acute inflammation induced by the biopsy of mouse mammary tumors promotes the development of metastasis Julia HobsonPhani GummadidalaMercedes Rincon Preclinical study 29 May 2013 Pages: 391 - 401
A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer N. U. LinD. S. SeahH. J. Burstein Clinical trial 05 May 2013 Pages: 403 - 410
A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer Hope S. RugoMario CamponeXavier Pivot Clinical trial Open access 07 May 2013 Pages: 411 - 419
Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients Pierre LévyJoseph GligorovAnne Fajac Clinical trial 11 May 2013 Pages: 421 - 428
Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors Michael P. LuxChristian M. BayerAlexander Hein Clinical trial 14 May 2013 Pages: 429 - 440
A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer Hiroji IwataNorikazu MasudaShinzaburo Noguchi Clinical Trial Open access 30 May 2013 Pages: 441 - 451
Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ Laura C. CollinsNinah AchacosoLaurel A. Habel Epidemiology 27 April 2013 Pages: 453 - 460
Adiponectin pathway polymorphisms and risk of breast cancer in African Americans and Hispanics in the Women’s Health Initiative Virginia G. KaklamaniThomas J. HoffmannChristos Mantzoros Epidemiology 30 April 2013 Pages: 461 - 468
Comorbidity and outcomes after surgery among women with breast cancer: analysis of nationwide in-patient sample database Ahmed DehalAli AbbasSamir Johna Epidemiology 30 April 2013 Pages: 469 - 476
Pretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers Chi-Chen HongSong YaoChristine B. Ambrosone Epidemiology 30 April 2013 Pages: 477 - 488
Time-dependent resource use and costs associated with different states of disease in patients diagnosed with HER-2-positive metastatic breast cancer G. W. J. FrederixJ. L. SeverensJ. H. M. Schellens Epidemiology 05 May 2013 Pages: 489 - 495
Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis Carmen A. PerezZachary S. ZumstegAlice Y. Ho Epidemiology 05 May 2013 Pages: 497 - 506
Beta blockers and angiotensin-converting enzyme inhibitors’ purported benefit on breast cancer survival may be explained by aspirin use Michelle D. HolmesSusan E. HankinsonWendy Y. Chen Epidemiology 07 May 2013 Pages: 507 - 513
Social networks, social support mechanisms, and quality of life after breast cancer diagnosis Candyce H. KroenkeMarilyn L. KwanLawrence H. Kushi Epidemiology 09 May 2013 Pages: 515 - 527
Postdiagnosis supplement use and breast cancer prognosis in the After Breast Cancer Pooling Project Elizabeth M. PooleXiaoOu ShuWendy Y. Chen Epidemiology 10 May 2013 Pages: 529 - 537
Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry E. C. InwaldM. Klinkhammer-SchalkeO. Ortmann Epidemiology Open access 16 May 2013 Pages: 539 - 552
Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer Jennifer KarleJuliane BolbrinkerAnne C. Regierer Epidemiology 18 May 2013 Pages: 553 - 560
Racial disparities in clinical presentation, surgical treatment and in-hospital outcomes of women with breast cancer: analysis of nationwide inpatient sample database Ahmed DehalAli AbbasSamir Johna Epidemiology 21 May 2013 Pages: 561 - 569
Simplifying clinical use of the genetic risk prediction model BRCAPRO Swati BiswasPhilamer AtienzaGiovanni Parmigiani Epidemiology 21 May 2013 Pages: 571 - 579
Patient–physician interaction and quality of life in recently diagnosed breast cancer patients Marilyn L. KwanEmily K. TamLawrence H. Kushi Epidemiology 29 May 2013 Pages: 581 - 595
Germline mutations in NF1 and BRCA1 in a family with neurofibromatosis type 1 and early-onset breast cancer Berta CamposJudith BalmañaOrland Díez Brief Report 27 April 2013 Pages: 597 - 602
Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research N. BouganimE. TsvetkovaE. Amir Brief Report 17 May 2013 Pages: 603 - 606
Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907 Rachel A. FreedmanBrandelyn Pitcherfor the Alliance for Clinical Trials in Oncology Brief Report 17 May 2013 Pages: 607 - 616
Methodological remarks concerning a recent meta-analysis on XPG Asp1104His and XPF Arg415Gln polymorphisms and breast cancer risk Qiliu PengXianjun LaoShan Li Letter to the Editor 26 April 2013 Pages: 617 - 618
What is the clinical significance of the volume of tissue excised in ROLL? Muneer AhmedMichael Douek Letter to the Editor 21 May 2013 Pages: 619 - 620